All In Biotech

Drug Trial Radar · NCT07504458

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

Mar 2027

Study completion Dec 2030

Sponsor

Lead sponsor
Quetzal TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 71 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Conditions

  • Acute Promyelocytic Leukemia (APL)
  • Acute Promyelocytic Leukaemia
  • Acute Promyelocytic Leukemia With PML-RARA
  • Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
  • Acute Promyelocytic Leukemia

Interventions

  • QTX-2101 + ATRADrug

    The experimental regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, QTX-2101 is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle.

  • IV arsenic trioxide (ATO) + ATRADrug

    The comparator regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, IV ATO is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIIITime frame: Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
  2. Molecular complete remission (molecular CR) rateTime frame: Up to 60 days of induction and 3 8-week cycles of consolidation treatment

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCI Health - UCI Medical Center

    Orange, California · Recruiting

  • Stanford University School of Medicine

    Stanford, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute at TriStar Centennial Medical Center

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia Health

    Charlottesville, Virginia · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François Magendie

    Bordeaux, France · Recruiting

  • CHU Grenoble Alpes - Hôpital Michallon

    La Tronche, France · Recruiting

  • Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de Brabois

    Nancy, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1

    Nice, France · Recruiting

  • Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital Nord

    Saint-Priest-en-Jarez, France · Recruiting

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France · Recruiting

  • Hospital Tor Vergata Roma

    Roma, Italy · Recruiting

  • Azienda ULSS 8 Berica - Ospedale San Bortolo

    Vicenza, Italy · Recruiting

  • Institutul Oncologic "Prof. Dr. Ion Chiricuță"

    Cluj-Napoca, Romania · Recruiting

  • Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol

    Badalona, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Universitario San Pedro de Alcántara

    Cáceres, Spain · Recruiting

  • Hospital Regional Universitario de Málaga

    Málaga, Spain · Recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain · Recruiting

  • Hospital Universitari Son Espases

    Palma de Mallorca, Balearic Islands, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.